Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.88 -2.5%	$8.11	$6.85 ▼ $19.89	$476.84M	-0.08	303,524 shs	225,546 shs
CRDL Cardiol Therapeutics	$1.07 -20.7%	$1.37	$0.77 ▼ $2.63	$111.61M	1.05	467,127 shs	4.35 million shs
GOSS Gossamer Bio	$1.98 -8.3%	$1.48	$0.66 ▼ $2.23	$490.97M	1.96	3.24 million shs	3.96 million shs
SVRA Savara	$2.74 +1.5%	$2.33	$1.89 ▼ $4.70	$466.66M	0.4	947,381 shs	395,564 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-2.48%	-3.43%	+6.20%	+1.19%	-54.24%
CRDL Cardiol Therapeutics	-20.74%	-27.70%	-26.21%	-6.15%	-46.77%
GOSS Gossamer Bio	-8.33%	-4.81%	+58.40%	+76.79%	+137.70%
SVRA Savara	+1.48%	+7.03%	+17.09%	-14.91%	-34.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	2.1561 of 5 stars	3.5	1.0	0.0	2.6	1.7	0.6
CRDL Cardiol Therapeutics	2.254 of 5 stars	3.7	4.0	0.0	1.1	0.0	0.6
GOSS Gossamer Bio	3.9334 of 5 stars	3.5	1.0	4.7	3.8	1.7	0.0
SVRA Savara	2.0124 of 5 stars	3.3	0.0	0.0	2.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	280.71% Upside
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	647.66% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	329.29% Upside
SVRA Savara	2.60	Moderate Buy	$5.60	104.38% Upside

Current Analyst Ratings Breakdown

Latest CRDL, GOSS, CGEM, and SVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/29/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.00
5/28/2025	SVRA Savara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$3.00 ➝ $2.00
5/28/2025	SVRA Savara	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $8.00
5/28/2025	SVRA Savara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
GOSS Gossamer Bio	$114.70M	3.92	N/A	N/A	$0.13 per share	15.23
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/14/2025 (Estimated)
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	8/11/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-344.81%	-537.92%	-43.96%	8/11/2025 (Estimated)
SVRA Savara	-$95.88M	-$0.48	N/A	N/A	N/A	N/A	-65.88%	-52.35%	8/11/2025 (Estimated)

Latest CRDL, GOSS, CGEM, and SVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.7951	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q1 2025	SVRA Savara	-$0.12	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	11.62	11.62
CRDL Cardiol Therapeutics	0.01	3.26	3.26
GOSS Gossamer Bio	6.70	5.71	5.71
SVRA Savara	0.20	14.91	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
CRDL Cardiol Therapeutics	12.49%
GOSS Gossamer Bio	81.23%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
CRDL Cardiol Therapeutics	5.25%
GOSS Gossamer Bio	6.70%
SVRA Savara	5.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.01 million	54.79 million	Optionable
CRDL Cardiol Therapeutics	20	82.68 million	78.34 million	Not Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
SVRA Savara	20	172.84 million	163.63 million	Optionable

CRDL, GOSS, CGEM, and SVRA Headlines

Recent News About These Companies

Savara (SVRA) Projected to Post Quarterly Earnings on Monday

August 5 at 10:27 AM | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Invests $381,000 in Savara Inc. (NASDAQ:SVRA)

August 4 at 3:29 AM | marketbeat.com

Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating

August 1, 2025 | msn.com

Savara: Repairing The Molbreevi aPAP Opportunity After RTF

July 22, 2025 | seekingalpha.com

Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

July 20, 2025 | marketbeat.com

Savara Announces New Employment Inducement Grant

July 18, 2025 | businesswire.com

Emerald Advisers LLC Raises Position in Savara Inc. (NASDAQ:SVRA)

July 13, 2025 | marketbeat.com

Emerald Mutual Fund Advisers Trust Purchases 638,568 Shares of Savara Inc. (NASDAQ:SVRA)

July 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

July 6, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 27, 2025 | prnewswire.com

Savara Independent Director Acquires 177% More Stock

June 25, 2025 | finance.yahoo.com

Richard J. Hawkins Purchases 48,225 Shares of Savara Inc. (NASDAQ:SVRA) Stock

June 24, 2025 | insidertrades.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 22, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 18, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 16, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 13, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 12, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 11, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 9, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, GOSS, CGEM, and SVRA Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.88 -0.20 (-2.48%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$7.60 -0.28 (-3.55%)

As of 04:00 AM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cardiol Therapeutics NASDAQ:CRDL

$1.07 -0.28 (-20.74%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$1.11 +0.04 (+3.74%)

As of 06:11 AM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Gossamer Bio NASDAQ:GOSS

$1.98 -0.18 (-8.33%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$1.70 -0.29 (-14.39%)

As of 04:00 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Savara NASDAQ:SVRA

$2.74 +0.04 (+1.48%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$3.00 +0.26 (+9.49%)

As of 04:00 AM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time